February 14, 2019 09:12 AM EST
Startups
Pharma

Ra­maswamy's Ax­o­vant whips up a CNS spin­off with a $530M deal and a syn­di­cate of sup­port­ers

Natalie Grover

Reporter

Af­ter beef­ing up its ar­se­nal of gene ther­a­pies-in-de­vel­op­ment in De­cem­ber fol­low­ing the strik­ing fail­ures of its once-hyped de­men­tia and Alzheimer’s as­sets, Vivek Ra­maswamy’s Ax­o­vant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

Up­dat­ed: J&J to buy In­tra-Cel­lu­lar for $14.6B in lat­est neu­ro­science bet

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

#JPM25 live blog day 1: How will Trump 2.0 im­pact the bio­phar­ma in­dus­try? Scott Got­tlieb, Bob Nelsen share ...

What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions

A service from the Financial Times